7 block­busters: An­a­lysts spot­light 2022’s crop of drugs most like­ly to win top mar­ket­ing sta­tus — 2 drugs dom­i­nate

Every year, the an­a­lysts over at Clar­i­vate is­sue their pre­dic­tions for which drugs will hit block­buster sta­tus.

Now in its 9th year, they’ve got some drugs — ei­ther pend­ing an FDA ap­proval or just won ap­proval, in the case of the asth­ma treat­ment teze­pelum­ab — that they think will be­come block­busters (i.e. hit $1 bil­lion in an­nu­al rev­enue) in the next five years. By the end of 2026, the an­a­lysts are ex­pect­ing about $16 bil­lion in sales from the top 7 drugs, and the top 2 can­di­dates — both from Eli Lil­ly — are pre­dict­ed to have an out-sized bite.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER